Compared to PI3K inhibitors, DNMT1 targeting demonstrated superior in vivo tumor suppression, mitigating the toxic effects of blood glucose variation caused by PI3K and PI3K-CDK inhibitor combinations. The gene discussed is DNMT1; the disease is neoplasm.